233 related articles for article (PubMed ID: 24793219)
1. Testing the therapeutic equivalence of alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin as monotherapy or in combination with metformin in patients with type 2 diabetes.
Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
Diabetes Ther; 2014 Jun; 5(1):341-4. PubMed ID: 24793219
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Kay S; Strickson A; Puelles J; Selby R; Benson E; Tolley K
Diabetes Ther; 2017 Apr; 8(2):251-273. PubMed ID: 28275958
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.
Li CJ; Liu XJ; Bai L; Yu Q; Zhang QM; Yu P; Yu DM
Diabetol Metab Syndr; 2014; 6():69. PubMed ID: 24917890
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison.
Craddy P; Palin HJ; Johnson KI
Diabetes Ther; 2014 Jun; 5(1):1-41. PubMed ID: 24664619
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
[TBL] [Abstract][Full Text] [Related]
8. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
Golightly LK; Drayna CC; McDermott MT
Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
10. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study.
Ofori-Asenso R; Ilomaki J; Chin KL; Mazidi M; Zomer E; Bell JS; Magliano DJ; Liew D
Diabetes Res Clin Pract; 2019 Dec; 158():107909. PubMed ID: 31697992
[TBL] [Abstract][Full Text] [Related]
12. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Tebboth A; Lee S; Scowcroft A; Bingham-Gardiner P; Spencer W; Bolodeoku J; Hassan SW
Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
[TBL] [Abstract][Full Text] [Related]
14. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.
Thomas MC; Paldánius PM; Ayyagari R; Ong SH; Groop PH
Diabetes Ther; 2016 Sep; 7(3):439-54. PubMed ID: 27502495
[TBL] [Abstract][Full Text] [Related]
15. Alogliptin: a new addition to the class of DPP-4 inhibitors.
Andukuri R; Drincic A; Rendell M
Diabetes Metab Syndr Obes; 2009 Jul; 2():117-26. PubMed ID: 21437125
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):999-1024. PubMed ID: 26173919
[TBL] [Abstract][Full Text] [Related]
17. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
Kalra S; Unnikrishnan AG; Agrawal N; Singh AK
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):197-202. PubMed ID: 21913883
[TBL] [Abstract][Full Text] [Related]
19. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
20. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
Guo WQ; Li L; Su Q; Dai WR; Ye ZL
Value Health; 2017 Dec; 20(10):1427-1430. PubMed ID: 29241903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
